Ulinastatin compared with Octreotide in severe acute pancreatitis: A Prospective observational study.

Background: Severe Acute pancreatitis (SAP) is a pancreatic inflammatory disease that has a high mortality. Ulinastatin, a urinary trypsin inhibitor that can be used in SAP. However, there are limited studies comparing Ulinastatin and octreotide in SAP. This study was done to study the efficacy of Ulinastatin in SAP patients in comparison with Octreotide. Methods: A prospective observational study was conducted among 49 SAP patients in the surgical in-patient unit at Goa medical college from January to March 2021. Patients either received Ulinastatin or Octreotide as part of their routine care and the institutional protocol. Various clinical outcomes, blood, and urine amylase levels were compared between two treatment groups. For statistical analysis SPSS version 20 was used. Results: The mean age of the patients was 40.31 ± 9.45 years. The cause of pancreatitis was alcohol usage in 42(85.71%), gallstones in 4 (8.16%), and pseudocyst in 3 (6.12%). Among the study population, 29 (59.18%) patients received Ulinastatin, and 20 (40.82%) received Octreotide. The mean blood amylase was 1452.11 ± 716.54 units per liter before treatment and 945.15 ± 397.03 after treatment. The mean urine amylase was 2432.37 ± 765.22 units per liter before treatment and 1064.7 ± 495.12 after treatment. The differences in the blood and urine amylase levels before and after treatment was statistically significant (P-value <0.001). Conclusion: This study has shown that Ulinastatin has better outcome than Octreotide in treatment of patients with severe acute pancreatitis. [ABSTRACT FROM AUTHOR]